stockrowSpruce Biosciences, Inc.
SPRBSpruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023.
- Revenue
- −75.9%
- EPS
- −90.9%
- Free cash flow
- −152.1%
- Total debt
- +427.2%
Quarter to June 2026, against a year earlier
Follow SPRB
Alert me
Spruce Biosciences, Inc. (SPRB) Piotroski F-score
Spruce Biosciences, Inc.'s Piotroski F-score for fiscal 2024 cannot be worked out: needs three fiscal years.
Piotroski F-score, annual
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (71.12%) | — | Fail | 0 |
| Positive operating cash flow | (55.96m) | (33.27m) | Fail | 0 |
| Rising return on assets | (71.12%) | — | n/a | — |
| Cash flow above net income | (2.93m) | 14.64m | Fail | 0 |
| Falling long-term leverage | 0.00 | — | n/a | — |
| Rising current ratio | 2.90 | 4.18 | Fail | 0 |
| No new shares issued | 550,000 | 512,200 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.07 | — | n/a | — |
| Piotroski F-score | n/a — needs three fiscal years | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CHRS Coherus Oncology, Inc. compare | 6 |
| CUE Cue Biopharma, Inc. compare | 5 |
| YARW Yarrow Bioscience, Inc compare | 3 |
| MOLN Molecular Partners AG Sponsored ADR compare | 2 |
| CMPX Compass Therapeutics, Inc. compare | — |
| SPRB Spruce Biosciences, Inc. | — |
| TARA Protara Therapeutics, Inc. compare | — |
| MENS Jyong Biotech Ltd. compare | — |
| PDSB PDS Biotechnology Corporation compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover